Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 71 Cash-to-Debt is 14.55 as of Jun. 2026, which is 15% above its 10-year median of 12.65. GuruFocus rates HMDCF with a GF Score™ of 71/100 and a GF Value™ of $2.42. The stock has 8 warning signs investors should review. Among 986 Drug Manufacturers companies, HUTCHMED (China) ranks better than 78.9% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. HUTCHMED (China)'s cash to debt ratio for the quarter that ended in Jun. 2026 was 14.55.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, HUTCHMED (China)could pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for HUTCHMED (China)'s Cash-to-Debt or its related term are showing as below:
HMDCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.22 Med: 12.65 Max: 1978.98
Current: 14.55
During the past 13 years, HUTCHMED (China)'s highest Cash to Debt Ratio was 1978.98. The lowest was 2.22. And the median was 12.65.
HMDCF's Cash-to-Debt is ranked better than 78.9% of 986
companies
in the Drug Manufacturers industry
Industry Median: 0.995
vs HMDCF: 14.55
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
HUTCHMED (China) Cash-to-Debt Related Terms
HUTCHMED (China) Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HUTCHMED (China) Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where HUTCHMED (China)'s Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (HMDCF) has a Cash-to-Debt of 14.55 as of Jun. 2026. This is 15% above median its historical median of 12.65. Over the past decade, HUTCHMED (China)'s Cash-to-Debt has ranged from 2.22 to 1,978.98. According to the industry distribution chart, HUTCHMED (China) ranks #208 out of 986 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is HUTCHMED (China)'s Cash-to-Debt too high?
HUTCHMED (China)'s current Cash-to-Debt of 14.55 is 15% above median its 10-year median of 12.65. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 1,978.98. The Drug Manufacturers industry median Cash-to-Debt is 1.00. HUTCHMED (China)'s value of 14.55 is 1362.3% above this industry median. Based on the distribution chart, HUTCHMED (China) ranks #208 out of 986 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #208 out of 986 companies for Cash-to-Debt. This places HUTCHMED (China) in the top 21% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.00. HUTCHMED (China)'s value of 14.55 is 1362.3% above this benchmark. Historically, HUTCHMED (China)'s own Cash-to-Debt has ranged from 2.22 to 1,978.98 over the past decade. While the company's 10-year median is 12.65 vs. the industry median of 1.00, HUTCHMED (China) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 986 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current Cash-to-Debt of 14.55 is 1362.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current Cash-to-Debt is 14.55, which is 15% above median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
HUTCHMED (China) (HMDCF) has a current Cash-to-Debt of 14.55. The stock's GF Value™ is $2.42, compared to a current price of $2.16 — trading 10.7% below its estimated fair value. The current Cash-to-Debt is 14.55, which is 15% above median its 10-year median of 12.65 and 1362.3% above the Drug Manufacturers industry median of 1.00. HUTCHMED (China)'s overall GF Score™ is 71/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current Cash-to-Debt is 14.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 10.7% below its estimated GF Value™ of $2.42.
Key valuation signals for HMDCF:
Cash-to-Debt: 14.55 (15% above median its 10-year median of 12.65)
GF Value™: $2.42 vs. price of $2.16 (10.7% below fair value)
Industry Position: 1362.3% above the Drug Manufacturers median (#208 of 986)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
71GF Score
Get the complete analysis for HMDCF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
